Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454532 | 0.83 | CYP2A6 (0.34) | CYP2A6TSHRGABRA1GABRB2ALDH1A1 | |
| SCHEMBL458006 | 0.82 | GABRA1 (0.31) | GABRA1GABRB2 | |
| SCHEMBL27891360 | 0.79 | ALDH1A1 (0.31) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27911681 | 0.79 | ALDH1A1 (0.31) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13518666 | 0.79 | ALDH1A1 (0.34) | TSHRALDH1A1GALR3RAB9AMAPT | |
| SCHEMBL28068347 | 0.79 | LOXL2 (0.34) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28006984 | 0.76 | — | — | |
| SCHEMBL58401 | 0.75 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL3644895 | 0.75 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL28027608 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057892-A1 | 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELARA PHARMACEUTICALS GMBH (DE) | 2011-05-19 | — | — | WO | claimed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2614053-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033225-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011057892-A1 | 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELARA PHARMACEUTICALS GMBH (DE) | 2011-05-19 | — | — | WO | disclosed |
| CN-1842516-A | Amide compounds and method for controlling plant diseases using the same | SUMITOMO CHEMICAL CO (JP) | 2006-10-04 | — | — | CN | disclosed |
| US-20060122064-A1 | Amides and method for plant diseases control with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1640360-A1 | AMIDES AND METHOD FOR PLANT DISEASE CONTROL WITH THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| CN-1301305-A | Serine protease variants with amino acid substitutions | PROCTER & GAMBLE (US) | 2001-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | CBR3, C5, CLN6 | CYP2A6 846/4885TSHR 1117/4885GABRA1 4273/4885 |
| US-20060122064-A1 | Amides and method for plant diseases control with the same | ARG1, ARGLU1, ARG2 | CYP2A6 2476/4885TSHR 851/4885GABRA1 3998/4885 |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | CYP2A6 47/4885TSHR 2629/4885GABRA1 2456/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | CYP2A6 47/4885TSHR 2629/4885GABRA1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.